TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7518728
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone treatment for 4 months in females
Study: 3177228
Drug: Diltiazem (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem (120 to 180 mg twice daily, mean dose 307 mg/day)
Study: 26887576
Drug: Aqua-cycling (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aqua-cycling (two 45-min sessions weekly for 12 weeks)
Study: 26259989
Drug: Ustekinumab half-standard
Normalized name: Ustekinumab
DrugBank: Ustekinumab (DB05679)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ustekinumab half-standard dosing (HSD)
Study: 26259989
Drug: Ustekinumab standard
Normalized name: Ustekinumab
DrugBank: Ustekinumab (DB05679)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ustekinumab standard dosing (SD)
Study: 21178616
Drug: Conventional-dose therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional-dose therapy (including bortezomib and immune-modulatory drugs)
Study: 19032132
Drug: Oxycodone PR/Naloxone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone PR/Naloxone PR
Study: 18708300
Drug: Oxycodone PR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone PR
Study: 17220048
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation of losartan (100 mg)
Study: 17220048
Drug: Reference formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference formulation of losartan (100 mg)
Study: 14694935
Drug: Palivizumab prophylaxis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palivizumab prophylaxis (5 monthly intramuscular injections at 15 mg/kg)
Study: 8595788
Drug: Tiagabine (TGB)
DrugBank: Tiagabine (DB00906)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tiagabine (TGB) hydrochloride as add-on therapy
Study: 1107360
Drug: Loxapine succinate
Normalized name: Loxapine Succinate
DrugBank: Loxapine (DB00408)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Loxapine succinate (40-80 mg daily)
Study: 1107360
Drug: Trifluoperazine (20-50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trifluoperazine (20-50 mg daily)
Study: 29138547
Drug: 5 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 μg tiotropium for 4 weeks
Study: 29138547
Drug: 150 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 μg indacaterol for 4 weeks
Study: 29138547
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy of tiotropium and indacaterol for 4 weeks
Study: 21447368
Drug: Laser irradiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laser irradiation (L)
Study: 21447368
Drug: Fluoride (AmF/NaF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoride (AmF/NaF gel) application (F)
Study: 19416526
Drug: LPS (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: LPS (4 ng/kg) administered intravenously
Study: 19416526
Drug: RWJ-67657 (p38
Approvals — FDA: no, EMA: no, PMDA: no
Description: RWJ-67657 (p38 MAP kinase inhibitor) administered 30 minutes before LPS infusion
Study: 9681666
Drug: Citalopram (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram (40 mg oral or intravenous for healthy subjects; 20 mg oral for patients with renal insufficiency or hepatic cirrhosis)
Study: 9681666
Drug: Citalopram (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram (20 mg oral for patients with hepatic cirrhosis)
Study: 1955122
Drug: Cisapride (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisapride (0.3 mg/kg PO t.i.d.)
Study: 31734696
Drug: CMV intravenous
Normalized name: CMV-immune globulin
DrugBank: Human cytomegalovirus immune globulin (DB13886)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CMV intravenous immunoglobulin (IVIG)
Study: 30597112
Drug: lemborexant 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: lemborexant 2.5 mg
Study: 2744064
Drug: zopiclone 7.5
Normalized name: zopiclone 7.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: zopiclone 7.5 mg
Study: 25378034
Drug: 5% oral
Normalized name: glucose 45% oral gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% oral glucose solution
Study: 21305270
Drug: ROSU 10
Normalized name: sulfacetamide
DrugBank: Sulfacetamide (DB00634)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ROSU 10 mg/day starting 5 days before the infusion of ZOL for a total period of 11 days
Study: 21305270
Drug: No ROSU
Approvals — FDA: no, EMA: no, PMDA: no
Description: No ROSU treatment
Study: 21305270
Drug: ROSU 10
Normalized name: sulfacetamide
DrugBank: Sulfacetamide (DB00634)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ROSU 10 mg/day
Study: 19824553
Drug: Oral-B Exceed
Normalized name: IODINE 5 g in 1 L TOPICAL SOLUTION [Exceed]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral-B Exceed toothbrush
Study: 30519955
Drug: Control intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control intervention (1.8 ml of 2% lidocaine with 1:100,000 adrenaline)
Study: 26260081
Drug: Dose of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose of cannabis consumption
Study: 21957588
Drug: Thymogen preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thymogen preparation administered by intranasal instillation of 100 mg once a day for 7 days before surgery
Study: 21957588
Drug: Isotonic sodium
Normalized name: ISOTONIC SODIUM CHLORIDE SOLUTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotonic sodium chloride solution (placebo) administered in the same scheme
Study: 19703279
Drug: Oxytocin 5
Normalized name: oxytocin 5 UNT/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxytocin 5 IU bolus and 40 IU infusion
Study: 19703279
Drug: Oxytocin 5
Normalized name: oxytocin 5 UNT/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxytocin 5 IU bolus and placebo infusion
Study: 17367495
Drug: CHF 4227
Normalized name: CHF 4227
DrugBank: CHF 4227 (DB05882)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHF 4227 (5-400 mg single doses)
Study: 17367495
Drug: CHF 4227
Normalized name: CHF 4227
DrugBank: CHF 4227 (DB05882)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHF 4227 (5-100 mg multiple doses)
Study: 17367495
Drug: CHF 4227
Normalized name: CHF 4227
DrugBank: CHF 4227 (DB05882)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHF 4227 (5 and 10 mg)
Study: 14702440
Drug: Drotrecogin alfa
Normalized name: Drotrecogin Alfa
DrugBank: Drotrecogin alfa (DB00055)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drotrecogin alfa (activated) at 24 micro g/kg per hour for 96 hours (part 2)
Study: 14702440
Drug: Drotrecogin alfa
Normalized name: Drotrecogin Alfa
DrugBank: Drotrecogin alfa (DB00055)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drotrecogin alfa (activated) at escalating doses of 6, 12, 24, and 36 micro g/kg per hour for 6 hours (part 1)
Study: 11736869
Drug: Alosetron 1
Normalized name: alosetron 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alosetron 1 mg twice daily for 15 days
Study: 11736869
Drug: Theophylline 200
Normalized name: theophylline 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theophylline 200 mg twice daily alone for 8 days
Study: 7628025
Drug: Oral midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral midazolam 0.5 mg.kg‐1
Study: 9243685
Drug: Diazepam 0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam 0.25 mg.kg‐1 with droperidol 0.25 mg.kg‐1
Study: 9243685
Drug: Trimeprazine 2
Normalized name: trimeprazine 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimeprazine 2 mg.kg‐1
Study: 8301808
Drug: Total parenteral
Normalized name: TPN - total parenteral nutrition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total parenteral nutrition alone (n = 21)
Study: 3718367
Drug: Oral fenoterol
Normalized name: fenoterol
DrugBank: Fenoterol (DB01288)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral fenoterol
Study: 23620935
Drug: Western medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western medicine (smectite powder and live combined bifidobacterium and lactobacillus tablets), orally administered.
Study: 21623600
Drug: sulodexide 75
Approvals — FDA: no, EMA: no, PMDA: no
Description: sulodexide 75 mg daily
Study: 21623600
Drug: sulodexide 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: sulodexide 150 mg daily
Study: 14759231
Drug: Amoxicillin/clavulanate 2000/125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin/clavulanate 2000/125 mg twice daily
Study: 16446376
Drug: Amoxicillin/clavulanate 875/125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin/clavulanate 875/125 mg three times daily
Study: 9834042
Drug: 10-minute intravenous
Normalized name: TAGETES MINUTA FLOWER OIL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-minute intravenous infusion of 5 microg x kg(‐1) hCRF
Study: 9834042
Drug: 180-minute intravenous
Normalized name: TAGETES MINUTA FLOWER OIL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 180-minute intravenous infusion of 5 microg x kg(‐1) hCRF
Study: 9834042
Drug: Subcutaneous administration
Normalized name: subcutaneous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous administration of hCRF (300, 600, or 1200 microg)
Study: 9834042
Drug: Repetitive administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Repetitive administration of hCRF
Study: 8077989
Drug: High-dose methotrexate
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose methotrexate (HDMTX) and fluorouracil (FU)
Study: 8077989
Drug: High-dose methotrexate
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose methotrexate (HDMTX) and fluorouracil (FU) with a 6-hour interval
Study: 49736
Drug: Propranolol (0-1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (0-1 mg/kg)
Study: 49736
Drug: Practolol (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Practolol (1 mg/kg)
Study: 49736
Drug: Acebutolol (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acebutolol (1 mg/kg)
Study: 30136743
Drug: Doll Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doll Therapy (DT)
Study: 28865924
Drug: 55.8 Gy
Approvals — FDA: no, EMA: no, PMDA: no
Description: 55.8 Gy (RBE) of fractionated combined proton-photon radiation therapy
Study: 28865924
Drug: 63.0 Gy
Approvals — FDA: no, EMA: no, PMDA: no
Description: 63.0 Gy (RBE) of fractionated combined proton-photon radiation therapy
Study: 28865924
Drug: Both doses
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both doses (55.8 Gy and 63.0 Gy)
Study: 21802303
Drug: Concurrent cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent cognitive task (silent backward counting)
Study: 19374676
Drug: Nasal cannulae
Normalized name: CANNULA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal cannulae (5 L/minute)
Study: 19374676
Drug: Oxygen mask
Normalized name: oxygen masks
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxygen mask (5 L/minute)
Study: 2663407
Drug: Aceclofenac 100
Normalized name: aceclofenac 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aceclofenac 100 mg
Study: 10961730
Drug: mesalamine 1
Normalized name: mesalamine 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: mesalamine 1 g two times a day plus Saccharomyces boulardii 1 g daily
Study: 10961730
Drug: mesalamine 1
Normalized name: mesalamine 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: mesalamine 1 g three times a day
Study: 1611155
Drug: Glyburide 10
Normalized name: Glyburide
DrugBank: Glyburide (DB01016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glyburide 10 mg/d
Study: 28394002
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g of omega-3 acids daily for 12 weeks
Study: 28394002
Drug: Placebo (corn
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (corn oil 1 g daily for 12 weeks)
Study: 23046851
Drug: Oral methamphetamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral methamphetamine (0, 8 or 16 mg)
Study: 16740174
Drug: PV measurement
Approvals — FDA: no, EMA: no, PMDA: no
Description: PV measurement using the constant flow method (PVCF); insufflated volume = 1120 +/- 115 ml, plateau pressure = 46 +/- 11 cmH2O
Study: 16740174
Drug: PV measurement
Approvals — FDA: no, EMA: no, PMDA: no
Description: PV measurement using a 2 l super syringe (PVSS); insufflated volume = 1824 +/- 381 ml, plateau pressure = 46 +/- 9 cmH2O
Study: 15356367
Drug: Antimicrobial wound
Normalized name: Anasept Antimicrobial Wound
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antimicrobial wound cleanser (0.057% sodium hypochlorite in isotonic saline solution)
Study: 10699770
Drug: Inhaled Entonox
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled Entonox (50% nitrous oxide, 50% oxygen)
Study: 10699770
Drug: Intravenous midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous midazolam and meperidine
Study: 9432334
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg lansoprazole once in the morning, 200 mg clarithromycin twice daily, and 250 mg metronidazole twice daily for 1 week (LCM1)
Study: 9432334
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg lansoprazole once in the morning, 200 mg clarithromycin twice daily, and 500 mg metronidazole twice daily for 1 week (LCM2)
Study: 3593624
Drug: Y-8894 50
Normalized name: Y
Approvals — FDA: no, EMA: no, PMDA: no
Description: Y-8894 50 mg
Study: 3593624
Drug: Nortriptyline 50
Normalized name: nortriptyline 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nortriptyline 50 mg
Study: 31918685
Drug: Ranibizumab treatment
Normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ranibizumab treatment guided by best-corrected visual acuity (BCVA) loss (Group I)
Study: 31918685
Drug: Ranibizumab treatment
Normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ranibizumab treatment guided by BCVA loss and/or signs of disease activity on optical coherence tomography (OCT; Group II)
Study: 30025734
Drug: USCDT with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: USCDT with 4 mg tPA/lung for 2 hours
Study: 30025734
Drug: USCDT with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: USCDT with 4 mg tPA/lung for 4 hours
Study: 30025734
Drug: USCDT with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: USCDT with 6 mg tPA/lung for 6 hours
Study: 30025734
Drug: USCDT with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: USCDT with 12 mg tPA/lung for 6 hours
Study: 25786048
Drug: Acetyl L-carnitine
Normalized name: Nature's Way Acetyl L-Carnitine Capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetyl L-carnitine 1500 mg/day (500 mg t.i.d.)
Study: 18203046
Drug: 5-HT stimulation
Normalized name: 5-HT
DrugBank: Serotonin (DB08839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-HT stimulation during treatment
Study: 18203046
Drug: Antidepressant treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressant treatment in patients with depression
Study: 16365055
Drug: Betaine 3
Normalized name: betaine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Betaine 3 g
Study: 16365055
Drug: Betaine 6
Normalized name: betaine 648 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Betaine 6 g
Study: 16365055
Drug: Betaine 1
Normalized name: betaine 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Betaine 1 g
Study: 16365055
Drug: Betaine (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Betaine (all doses)
Study: 14564940
Drug: Multi‐micronutrient supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multi‐micronutrient supplement (S)
Study: 14564940
Drug: Multi‐micronutrient supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multi‐micronutrient supplement plus test meal (MS)
Study: 6588726
Drug: Fluoride varnish
Normalized name: Hydrogen fluoride
DrugBank: Hydrogen fluoride (DB11072)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoride varnish treatment every 6 months
Study: 29926431
Drug: Therapeutic education
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic education programme 'PETAL' for laryngectomised patients and their close relations; details on dosage and duration not specified.
Study: 29926431
Drug: Pilot phase
Normalized name: Picot
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pilot phase of the programme; details on dosage and duration not specified.
Study: 29926431
Drug: Prospective intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prospective intervention 'replication' phase; details on dosage and duration not specified.
Study: 29926431
Drug: Cluster-randomised multicentric
Normalized name: cluster fig extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cluster-randomised multicentric comparative intervention phase; details on dosage and duration not specified.
Study: 29144178
Drug: Evening-dosing of
Normalized name: methylphenidate
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Evening-dosing of DCF regimen
Study: 29144178
Drug: Morning-dosing of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morning-dosing of DCF regimen
Study: 26853293
Drug: Subepidermal triamcinolone
Normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subepidermal triamcinolone injections (4mg per cc, 5mm intervals until complete blanching)
Study: 20207720
Drug: 100% of
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100% of the RDA for SAA, 15 mg/kg APAP given on day 3
Study: 20207720
Drug: 0% of
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0% of the RDA for SAA, 15 mg/kg APAP given on day 3
Study: 9590466
Drug: KA 672-HCl
Normalized name: bismuth subsalicylate
DrugBank: Bismuth subsalicylate (DB01294)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: KA 672-HCl 40 mg single dose
Study: 9590466
Drug: KA 672-HCl
Normalized name: bismuth subsalicylate
DrugBank: Bismuth subsalicylate (DB01294)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: KA 672-HCl 60 mg single dose
Study: 9590466
Drug: KA 672-HCl
Normalized name: bismuth subsalicylate
DrugBank: Bismuth subsalicylate (DB01294)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: KA 672-HCl 10 mg repeated doses for 14 days
Study: 9590466
Drug: KA 672-HCl
Normalized name: bismuth subsalicylate
DrugBank: Bismuth subsalicylate (DB01294)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: KA 672-HCl 20 mg repeated doses for 14 days
Study: 9590466
Drug: KA 672-HCl
Normalized name: bismuth subsalicylate
DrugBank: Bismuth subsalicylate (DB01294)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: KA 672-HCl repeated doses
Study: 9590466
Drug: KA 672-HCl
Normalized name: bismuth subsalicylate
DrugBank: Bismuth subsalicylate (DB01294)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: KA 672-HCl single dose
Study: 9590466
Drug: KA 672-HCl
Normalized name: bismuth subsalicylate
DrugBank: Bismuth subsalicylate (DB01294)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: KA 672-HCl 20 mg single dose
Study: 9590466
Drug: KA 672-HCl
Normalized name: bismuth subsalicylate
DrugBank: Bismuth subsalicylate (DB01294)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: KA 672-HCl 20 mg repeated doses
Study: 3384164
Drug: Amoxycillin/clavulanic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxycillin/clavulanic acid (2.2 g preoperative dose)
Study: 3384164
Drug: Cefuroxim (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefuroxim (1.5 g) combined with Metronidazole (0.5 g)
Study: 31010007
Drug: CIPA nutrition
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: CIPA nutrition screening and treatment
Study: 24120754
Drug: Progressive Resistance
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Progressive Resistance Training (PRT) programme, trained twice a week for 10 weeks at a community gymnasium with a physiotherapy student mentor using pin-loaded weight machines
Study: 27287343
Drug: Active PEMF
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active PEMF treatment
Study: 21493648
Drug: S/GSK1349572 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: S/GSK1349572 50 mg with multivitamin (MVI; One A Day Maximum)
Study: 21493648
Drug: S/GSK1349572 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: S/GSK1349572 50 mg with liquid antacid (Maalox Advanced Maximum Strength)
Study: 21493648
Drug: S/GSK1349572 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: S/GSK1349572 50 mg 2 h before an antacid
Study: 17110827
Drug: n-3 polyunsaturated
Normalized name: Omega-3 (n-3) polyunsaturated fatty acids
Approvals — FDA: no, EMA: no, PMDA: no
Description: n-3 polyunsaturated fatty acids (3 g daily)
Study: 11696730
Drug: Intrarectal 2%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrarectal 2% lidocaine gel
Study: 2162027
Drug: Rhesus rotavirus
Normalized name: rotavirus vaccine, live attenuated, G1P[8] human 89-12 strain Oral Suspension [Rotarix]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rhesus rotavirus vaccine serotype 3 (RRV) 10(5) pfu
Study: 2162027
Drug: Rhesus rotavirus
Normalized name: rotavirus vaccine, live attenuated, G1P[8] human 89-12 strain Oral Suspension [Rotarix]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rhesus rotavirus vaccine serotype 3 (RRV) 10(4) pfu
Study: 2162027
Drug: Rhesus rotavirus
Normalized name: rotavirus vaccine, live attenuated, G1P[8] human 89-12 strain Oral Suspension [Rotarix]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rhesus rotavirus vaccine serotype 3 (RRV) 10(3) pfu
Study: 31126566
Drug: Lentil savigh
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lentil savigh (roasted lentil flour) 30 grams daily (three 10-gram sachets in the morning)
Study: 31126566
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid 500 mg every eight hours
Study: 22330824
Drug: 1500 mg
Normalized name: inulin 1500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1500 mg V0191 once daily for 24 weeks
Study: 22330824
Drug: Matching placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo once daily for 24 weeks
Study: 17617941
Drug: High tomato
Normalized name: Tomato
DrugBank: Tomato (DB10573)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High tomato diet (400 ml tomato juice and 30 mg tomato ketchup daily)
Study: 12065987
Drug: Standard surgical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard surgical treatments for intervertebral disc herniation
Study: 12065987
Drug: Standard surgical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard surgical treatments for spinal stenosis
Study: 12065987
Drug: Standard surgical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard surgical treatments for degenerative spondylolisthesis